Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

IGF-1 vs MGF

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

IGF-1: AMGF: D
AttributeIGF-1MGF
CategoryGrowth FactorGrowth Factor
Evidence RatingAFDA ApprovedDPreclinical
Clinical StatusFDA-approved (Increlex/mecasermin) for severe primary IGF-1 deficiency.Preclinical only. No human clinical trials.
MechanismIGF-1 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates the PI3K/Akt pathway (promoting cell survival and protein synthesis) and the MAPK/ERK pathway (promoting cell proliferation). In circulation, 95-99% of IGF-1 is bound to IGF binding proteins, primarily IGFBP-3 in a...MGF is expressed as part of the IGF-1 gene through alternative splicing in response to mechanical overload or tissue damage. The E-domain peptide (distinct from the mature IGF-1 peptide) activates satellite cells — muscle stem cells that donate nuclei to growing or repairing muscle fibers. It upregu...
Half-Life~10-15 min (free); ~12-15 hours (bound to IGFBP-3/ALS complex)Minutes (non-PEGylated); rapidly degraded by serum proteases
Bioavailability~100% (subcutaneous)
Molecular Weight~7649 g/mol
WADA StatusProhibitedProhibited
Research Half-Life~10-15 min (free); ~12-15 hours (bound to IGFBP-3/ALS complex)Minutes (non-PEGylated); rapidly degraded by serum proteases
Key Use Cases
  • IGF-1 Deficiency Treatment
  • Reference
  • Muscle Research
Safety Concerns
  • Hypoglycemia is the most common and serious adverse effect (FDA black box warning on Increlex) — occurs in up to 50% of patients
  • Must be administered with a meal to reduce hypoglycemia risk
  • Injection site reactions common
  • No human safety data exists
  • Theoretical risks include uncontrolled cell proliferation
  • Extremely short half-life of the non-PEGylated form may limit both efficacy and toxicity
Contraindications
  • Active or suspected malignancy
  • Allergy to mecasermin or any excipient
  • Closed epiphyses (for growth indication)
  • IV administration (must be subcutaneous)
  • Active cancer or history of cancer (growth factor concern)
  • Pregnancy and breastfeeding (no safety data)
Regulatory (US)FDA-approved (Increlex, mecasermin) for severe primary IGF-1 deficiency. WADA-banned.Not FDA-approved. Research chemical only. WADA-banned.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationIGF-1MGF
Purity Standard≥98%≥98%
CAS NumberN/AN/A
Molecular FormulaN/AN/A
Available Formats1mg2mg
Batch COAs Published
Stock StatusOut of stockOut of stock

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.